Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

End Stage Renal Disease Clinical Trial

Official title:

Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02453646
• Other study ID #: TR 0147
• Status: Completed
• Phase: N/A
• Start date: April 2015
• Est. completion date: July 2018

Study information

• Verified date: September 2018
• Source: Marvao Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A U.S. multi-centre post approval registry to analyse the CRBSI rate in patients with the NexSite HD Catheter for long term vascular access for hemodialysis.

Description:

This is a U.S. multi - centre, prospective, non-randomized post approval registry. Approximately one hundred and twenty patients will be implanted with a NexSite HD catheter at four to eight U.S. sites where hemodialysis catheters are routinely implanted. Each site may enrol a maximum of 50 patients. Enrolled patients will be followed from device placement to device removal or 180 days post device placement. Patients will be enrolled once only.

The primary endpoint is CRBSI rate related to the NexSite HD catheter. Determination of infection will be decided by the investigator and if necessary adjudicated by the CEC (Clinical Events Committee) based on blood culture results, regardless of whether the catheter is removed.

Secondary endpoints for the study are

• Successful placement and continued use of the NexSite HD device designed for use in patients requiring long term hemodialysis.

• Healing of catheter exit site

• Tunnel Infections

• Exit site infections

• Early non-infectious complications associated with CVCs

• Late non-infectious complications associated with Central Venous Catheters

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: July 2018
• Est. primary completion date: September 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. The patient shall be 18 - 80 years old.

2. The patient requires the placement of a long term tunnelled HD catheter for administration of hemodialysis.

3. The patient has anticipated survival in excess of 90 days from the anticipated date of catheter placement.

4. The patient has the ability to understand the research subject information and sign a written Informed Consent form which must be obtained prior to initiation of the study.

5. The patient receives the catheter via the internal jugular or subclavian vein.

6. All female patients of child bearing potential must complete a negative pregnancy test and will confirm that they are not breastfeeding.

Exclusion Criteria:

1. The patient is participating in another IRB (Institutional Review Board) clinical trial, which modifies standard-of-care treatment and/or involves an investigational device or drug.

2. The patient has a confirmed or suspected infection, bacteraemia or septicaemia.

3. The patient's physiology is NOT suitable for placement of the NexSite device; this will include an examination of the anatomy at the proposed catheter exit site.

4. The patient is known or suspected to have allergies to the materials used in the construction of the device.

5. The patient has previously suffered from coagulation issues or has had vascular surgery at the proposed placement site.

6. The patient has received radiation treatment at the proposed catheter placement site.

7. The patient has severe chronic obstructive lung disease.

8. The patient is pyretic within 72 hours (temperature =38o C or 100.4oF) prior to placement and/or has received antimicrobial drugs within two weeks prior to catheterisation.

9. The patient is female of child bearing potential not using adequate contraception. (Adequate contraception is defined as abstinence, intrauterine device [IUD], birth control pills, or spermicidal gel with diaphragm or condom)

10. The patient has another indwelling catheter.

11. The patient has non-healing diabetic foot ulcers.

12. The patient did not give informed consent.

13. The patient would be unavailable for follow-up.

14. The patient is a permanent nursing home resident.

15. The proposed access site is not the internal jugular or subclavian vein.

16. The patient is scheduled to undergo an elective surgical procedure (other than a procedure to create a graft or fistula) within the study timeframe.

17. Any other condition that the Investigator believes should exclude the patient from the study.

18. The patient does not have English or Spanish as their first language.

Related Conditions & MeSH terms

• End Stage Renal Disease
• Kidney Failure, Chronic

Intervention

Device:
• NexSite HD Patients
Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.

Locations

Country	Name	City	State
United States	Eastern Nephrology Associates	Greenville	North Carolina
United States	Lubbock Vascular Access Centre	Lubbock	Texas
United States	Eastern Nephology Associates	New Bern	North Carolina
United States	South Carolina Nephrology and Hypertension Center Inc	Orangeburg	South Carolina
United States	Capital Nephrology Associates	Raleigh	North Carolina
United States	Renal Associates	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Marvao Medical

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with Catheter-Related Blood Stream Infection (CRBSI)(bacteremia/fungemia) as an adverse event.	Number of participants with a confirmed CRBSI for the duration of catheter use or to 180 days post device placement (whichever occurs first)	Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Secondary	Number of participants with adverse events associated with device placement and use.	Number of participants with adverse events associated with device placement and for the duration of catheter use or to 180 days post device placement.	Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Secondary	Number of participants with unhealed catheter exit sites	Number of participants with unhealed exit sites for the duration of catheter use or to 180 days post device placement (whichever occurs first)	Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Secondary	Number of participants with tunnel infection as an adverse event	Number of participants with a tunnel infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)	Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Secondary	Number of participants with exit site infection as an adverse event	Number of participants with a exit site infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)	Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Secondary	Number of participants with Pneumothorax, haemothorax, arrhythmia, air embolism or arterial perforation as an adverse event.	Number of participants with non-infectious catheter complications within one day of placement.	1 day of device placement
Secondary	Number of participants with Catheter dislodgement, Catheter tip dislodgement and catheter thrombosis as an adverse event.	Number of participants with late non infectious complications for the duration of catheter use or to 180 days post device placement (whichever occurs first).	Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)